Virological rebound after suppression on highly active antiretroviral therapy

Objective: To determine the rate of virological rebound and factors associated with rebound among patients on highly active antiretroviral therapy (HAART) with previously undetectable levels of viraemia. Design: An observational cohort study of 2444 patients from the EuroSIDA study. Methods: Patients were followed from their first viral load under 400 copies/ml to the first of two consecutive viral loads above 400 copies/ml. Incidence rates were calculated using person-years of follow-up (PYFU), Cox proportional hazards models were used to determine factors related to rebound. Results: Of 2444 patients, 1031 experienced virological rebound (42.2%). The incidence of rebound decreased over time; from 33.5 in the first 6 months after initial suppression to 8.6 per 100 PYFU at 2 years after initial suppression (P < 0.0001). The rate of rebound was lower for treatment-naive compared with treatment-experienced patients. In multivariate models, patients who changed treatment were more likely to rebound, as were patients with higher viral loads on starting HAART. Treatment-naive patients were less likely to rebound. Among pretreated patients, those who were started on new nucleosides were less likely to rebound. Conclusion: The rate of virological rebound decreased over time, suggesting that the greatest risk of treatment failure is in the months after initial suppression. Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response.

[1]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  J. Nielsen,et al.  Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[3]  Julio S. G. Montaner,et al.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.

[4]  A. Mocroft,et al.  Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.

[5]  J. Rockstroh,et al.  Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. , 1997, AIDS.

[6]  J. Leonard,et al.  The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.

[7]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[8]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[9]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[10]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[11]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[12]  P. Reiss,et al.  Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. , 1999, The Journal of infectious diseases.

[13]  C. Sabin,et al.  Virological response to protease inhibitor therapy in an HIV clinic cohort. , 1999, AIDS.

[14]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[15]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[16]  A. Mocroft,et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.

[17]  D. Cooper,et al.  Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy , 2000, AIDS.

[18]  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy , 2000 .

[19]  A. Phillips,et al.  Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population , 2000, AIDS.

[20]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[21]  D. Costagliola,et al.  Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor , 2000, AIDS.

[22]  R. Grant,et al.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.

[23]  A. Mocroft,et al.  Participation in clinical studies among patients infected with HIV‐1 in a single treatment centre over 12 years , 2000, HIV medicine.

[24]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.

[25]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2000, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[26]  V. Calvez,et al.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.

[27]  C. Sabin,et al.  Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals , 2001, AIDS.

[28]  D. Neau,et al.  Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996‐1998 , 2001, Journal of acquired immune deficiency syndromes.

[29]  O. Kirk,et al.  Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients , 2001, AIDS.

[30]  M. Sprangers,et al.  Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. , 2001, Archives of internal medicine.

[31]  Bg Gazzard and.  British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.

[32]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[33]  D. Neau,et al.  Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. , 2001 .

[34]  Amalio Telenti,et al.  Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. , 2002, AIDS.

[35]  F. Brun-Vézinet,et al.  Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen , 2002, AIDS.

[36]  A. Gifford,et al.  Participation in research and access to experimental treatments by HIV-infected patients. , 2002, The New England journal of medicine.

[37]  B. Gazzard,et al.  Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study , 2002, AIDS.

[38]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[39]  M. Moroni,et al.  Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. , 2002, The Journal of infectious diseases.

[40]  C. Sabin,et al.  Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. , 2002, The Journal of infectious diseases.